Long Term Prospective Study of Tai Chi Intervention to Prevent MCI From Conversion to Dementia

Overview

This study evaluates the effects of 3 years-Tai Chi exercise intervention on cognitive function in MCI patients and to clarify whether the intervention can prevent MCI from conversion to dementia. Patients will be randomized into the Tai chi training group and the control group.

Detailed description

Dementia is a syndrome of impairments of cortical functions caused by brain diseases. More than 55 million people worldwide are currently living with dementia, with nearly 10 million new cases each year. Alzheimer's disease is the most common form of dementia and may account for 60-70% of patients with dementia. Mild cognitive impairment (MCI) is an intermediate state between normal cognitive aging and dementia. About 10% to 15% of patients with MCI progress to dementia each year. Therefore, it is crucial to find intervention strategies to prevent the progression of MCI to dementia. However, drug interventions are currently ineffective in the prevention of dementia. Based on the synaptic plasticity, more and more studies focus on non-drug interventions. Our research group previously found 6-months non-drug interventions (cognitive training, exercise therapy) can effectively delay cognitive decline in the elderly, providing a new strategy for the improvement of cognition in the elderly. Therefore, this project plans to conduct a multi-site, randomized, parallel-controlled clinical trial to examine the effect of 3 years-Tai Chi exercise intervention on cognitive function in MCI patients and to clarify whether the intervention can prevent MCI from conversion to dementia.

Interventions

• Behavioral Tai chi training
  Tai chi, also called tai chi chuan, is an ancient Chinese form of exercise originally created as a fighting art. It is a kind of gentle physical exercise and stretching, which involves a series of movements performed in a slow, focused manner and accompanied by deep breathing.
• Behavioral Group activity
  A organizer will lead the subjects to participate in group activities once a quarter. In group activities, there will be popular science lectures and interactive games.

Primary outcome measures

• Incidence of MCI converted to Alzheimer's disease. [Time frame: 36 months]
• The global cognitive function of MCI patients. [Time frame: 18 months and 36 months]

Secondary outcome measures (12)

• Memory [Time frame: 18 months and 36 months]
• Attention [Time frame: 18 months and 36 months]
• Executive function [Time frame: 18 months and 36 months]
• Language [Time frame: 18 months and 36 months]
• Working memory test [Time frame: 18 months and 36 months]
• Visual spatial ability [Time frame: 18 months and 36 months]
• Change from baseline in MMSE score [Time frame: 18 months and 36 months]
• Change from baseline in MoCA score [Time frame: 18 months and 36 months]
• Change from baseline in CDR score [Time frame: 18 months and 36 months]
• Activities of daily living [Time frame: 18 months and 36 months]
• Anxiety [Time frame: 18 months and 36 months]
• Depression [Time frame: 18 months and 36 months]

Eligibility criteria

Inclusion criteria

• Male and female participants aged 55 to 85 years (inclusive) at the time of screening
• Willing and able to give informed consent by GCP and local guidance.
• Meets the National Institute on Aging of the National Institutes of Health and Alzheimer's Association (NIA-AA) diagnostic criteria for "Mild Cognitive Impairment Due to Alzheimer's Disease" (2011); does not meet the American Psychiatric Association's diagnostic criteria Diagnostic and Statistical Manual of Mental Disorders, Revised IV (DSM-IV-R) diagnostic criteria for dementia;
• Main complaint of memory loss, 24≤MMSE and/or 17≤MOCA<26 points, with one or more cognitive domains impairments;
• CDR global score of 0.5, with memory box score ≥0.5
• Functional activities questionnaire (FAQ) <5
• Hachinski ischemia score ≤4;
• Have the physical, cognitive, listening, speech, literacy and language skills necessary to participate in all tests;
• Capable of performing MR
• Allowed and Prohibited concomitant and treatments.

During the clinical study, the following drugs are prohibited:

Acetylcholinesterase inhibitors, N-methyl-D-aspartate (NMDA) antagonists (eg, memantine, amantadine, ketamine, and dextromethorphan), adrenal corticosteroids, central nervous system stimulants, traditional Chinese medicine and various medicines that can improve memory or cognition;

During the clinical study, the following drugs cannot be added:

Antipsychotics, antidepressants, sedative-hypnotics for sleep (zopiclone, alprazolam, estazolam can be used temporarily if necessary) For long-term use of the above drugs, the dose should be kept as stable as possible during the study.

Exclusion criteria

• Cognitive impairment caused by other reasons (for example) cerebrovascular disease, central nervous system infection, Creutzfeldt-Jakob disease, Huntington's disease, Parkinson's disease, dementia with Lewy bodies, trauma, other physical and chemical factors (drugs, alcohol, CO, etc.), important physical diseases (hepatic encephalopathy, pulmonary encephalopathy, etc.), brain tumor, endocrine diseases (thyroid disease, parathyroid disease), and vitamin deficiency or any other cause of dementia;
• Abnormal folate, thyroid, and/or vitamin B12 values that cannot be corrected before baseline visit.
• Major structural brain disease as judged by central MRI Diagnostic Imaging Review Team (eg, ischemic infarcts, subdural hematoma, hemorrhage, hydrocephalus, brain tumors, multiple subcortical ischemic lesions. or a single lesion in a critical region \[eg, thalamus\]). Mild white matter changes without clinical significance and no more than 2 lacunar infarcts are permitted.
• Mental illness determined by Diagnostic and Statistical Manual of Mental Disorders (DSM) V criteria, that is unstable within 12 months, or would interfere with study assessments, including schizophrenia or other psychotic disorders, bipolar disorder, severe depression, or delirium.
• DSM V diagnosis of alcohol or other substance abuse dependence within the last 12 months.
• History or current diagnosis of significant cardiac arrhythmias, myocardial infarction, transient ischemic attack, or cerebrovascular accident, uncompensated congestive heart failure New York Heart Association class III and IV.
• Major medical illness or unstable medical condition within 6 months of screening that in the opinion of the investigator may interfere with the participant's ability to comply with study procedures and abide by study restrictions, or with the ability to interpret safety data, including any physical disability (eg. blindness. deafness, non-cognitive related speech impairment, sensory or motor dysfunction) that would prevent completion of study procedures or assessments.
• Cancer except:

• History of any cancer that has been in remission (no evidence of recurrence) for > 3 years from the screening
• Participants with basal cell or stage I squamous cell carcinoma of the skin, stable untreated cancer as prostate or meningioma.
• Exercise regularly within 6 months prior to screening.
• Participants are excluded if they

• have participated in any other clinical study within 4 weeks prior to screening visit
• have participated in another Tai chi clinical study at any time
• plan to take part in another clinical study during this study.
• Geriatric Depression Scale-15(GDS-15) total score > 7 at screening
• The researcher estimates that the subject's compliance is poor, and it is believed that the subject is unlikely to complete the study.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Single blind

Primary purpose

Prevention

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT05310890 · TIME study

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗